Literature DB >> 17100995

PKD2 gene mutation analysis in Korean autosomal dominant polycystic kidney disease patients using two-dimensional gene scanning.

W Chung1, H Kim, Y H Hwang, S Y Kim, A-R Ko, H Ro, K B Lee, J S Lee, K-H Oh, C Ahn.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is genetically heterogeneous and is caused by mutations in the PKD1 or PKD2 genes. ADPKD caused by PKD2 mutations is characterized by a longer survival and a later onset of end-stage renal disease than ADPKD caused by PKD1 mutations. PKD2 encodes a 2.9-kb messenger RNA and is derived from 15 exons. Two-dimensional gene scanning (TDGS) is more efficient in detecting mutations in genes such as PKD2 because it can scan the whole coding regions simultaneously. In order to determine the prevalence of Korean PKD2 patients, all the coding sequences of PKD2 were screened using TDGS and direct sequencing in 46 randomly selected ADPKD patients (group 1). Another 45 ADPKD patients (group 2), who were presumed to be PKD2 patients, were screened in order to identify the type of mutation in the Korean PKD2 patients. Eight novel different mutations and three known mutations in the PKD2 gene were detected in 17 patients: 6 patients (13.0%) in group 1 and 11 patients (24.4%) in group 2. Considering the sensitivity of TDGS, the prevalence of PKD2 in Korean population might be greater than 18.6%. Both known and novel mutations were identified by TDGS in Korean PKD2 patients. Overall, these results showed that TDGS might be useful for diagnosing PKD2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17100995     DOI: 10.1111/j.1399-0004.2006.00721.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  6 in total

1.  Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin.

Authors:  Djalila Mekahli; Jean-Paul Decuypere; Eva Sammels; Kirsten Welkenhuyzen; Joost Schoeber; Marie-Pierre Audrezet; Anniek Corvelyn; Georges Dechênes; Albert C M Ong; Martijn J Wilmer; Lambertus van den Heuvel; Geert Bultynck; Jan B Parys; Ludwig Missiaen; Elena Levtchenko; Humbert De Smedt
Journal:  Pflugers Arch       Date:  2013-11-06       Impact factor: 3.657

2.  Identification of novel PKD1 and PKD2 mutations in Korean patients with autosomal dominant polycystic kidney disease.

Authors:  Rihwa Choi; Hayne Cho Park; Kyunghoon Lee; Myoung-Gun Lee; Jong-Won Kim; Chang-Seok Ki; Young-Hwan Hwang; Curie Ahn
Journal:  BMC Med Genet       Date:  2014-12-10       Impact factor: 2.103

3.  Novel mutations of PKD genes in the Czech population with autosomal dominant polycystic kidney disease.

Authors:  Lena Obeidova; Veronika Elisakova; Jitka Stekrova; Jana Reiterova; Miroslav Merta; Vladimir Tesar; Frantisek Losan; Milada Kohoutova
Journal:  BMC Med Genet       Date:  2014-04-03       Impact factor: 2.103

4.  PKD2 mutation in an Iranian autosomal dominant polycystic kidney disease family with misleading linkage analysis data.

Authors:  Mona Entezam; Mohammad Reza Khatami; Fereshteh Saddadi; Mohsen Ayati; Jamshid Roozbeh; Mohammad Keramatipour
Journal:  Kidney Res Clin Pract       Date:  2016-02-27

5.  Identifying gene mutations of Chinese patients with polycystic kidney disease through targeted next-generation sequencing technology.

Authors:  Tao Wang; Qinggang Li; Shunlai Shang; Guangrui Geng; Yuansheng Xie; Guangyan Cai; Xiangmei Chen
Journal:  Mol Genet Genomic Med       Date:  2019-05-06       Impact factor: 2.183

6.  Co-occurrence of neurofibromatosis type 1 and optic nerve gliomas with autosomal dominant polycystic kidney disease type 2.

Authors:  Ramón Peces; Rocío Mena; Yolanda Martín; Concepción Hernández; Carlos Peces; Dolores Tellería; Emilio Cuesta; Rafael Selgas; Pablo Lapunzina; Julián Nevado
Journal:  Mol Genet Genomic Med       Date:  2020-06-13       Impact factor: 2.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.